Moreover, while TRPM6 was not initially predicted the moderate inhibitory active is worth investigating. TRPM6 inhibition is not fully elucidated, however, it is mainly involved in magnesium homeostasis in the intestine and kidney and it has been demonstrated to have expression levels modulated by hormones such as estrogen and angiotensin II,(66) immunosuppressant(67) and diuretics drugs,(68) and epidermal growth factor (EGF).( ) Moreover, the decreased expression of TRPM6 in cancer patients treated with EGFR targeted therapies (e.g., cetuximab) seems to positively contribute to the oncologic efficacy of these therapies, as decreased magnesium availability inhibits cell proliferation and slows down tumor growth.(70,71) Thus, we encourage further investigation on clinical relevance of TRPM6 inhibition by tofacitinib in oncology.